Efficacy of varicella (VZV) vaccination: an update for the clinician
Authors:
Open Access
- 1 January 2016
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Vaccines
- Vol. 4 (1-2) , 20-31
Abstract
Varicella-zoster virus (VZV) infection causes two distinct clinical conditions. Primary varicella infection results in chickenpox, a contagious rash illness typically seen among children. VZV can reactivate years after the initial infection to cause herpes zoster (HZ) and lead to post-herpetic neuralgia, a common complication resulting in persistent pain that may last for years after the zoster rash resolves. A person’s risk of having longer lasting and more severe pain associated with HZ increases with age. Since the introduction of VZV vaccines, the rates of infection, hospitalizations, and mortality have declined. In this review, we discuss in detail current VZV vaccines available for the prevention of VZV and HZ infections. Varilrix (GSK Biologicals, UK), Varivax (Merck, USA) and the combined measles, mumps, rubella, and varicella (MMRV) vaccine contain the live attenuated Oka strain of VZV for routine varicella vaccination. While Zostavax is the only HZ vaccine currently approved for use in the United States and the European Union [EMEA, 2011], a subunit vaccine candidate called HZ/su has recently shown improved efficacy for zoster prevention in two clinical trial phase III studies. VariZIG, a post-exposure prophylactic, uses zoster immune globulin to prevent VZV infection in those who have recently been in contact with VZV but lack evidence of varicella immunity and are contraindicated to receive the varicella vaccine. Further, we discuss the skin tropic and neurotropic factor VZV ORF7 gene and its involvement in varicella infection, reactivation and latency in ganglia. Ultimately, these studies can contribute to the development of a neuroattenuated vaccine candidate against varicella or a vector for delivery of other virus antigens.Keywords
This publication has 97 references indexed in Scilit:
- Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort StudyPLOS Medicine, 2013
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- The Varicella-Zoster Virus Genome2010
- The Incidence and Clinical Characteristics of Herpes Zoster Among Children and Adolescents After Implementation of Varicella VaccinationThe Pediatric Infectious Disease Journal, 2009
- Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: Uptake of the first new vaccine to target seniorsVaccine, 2009
- Varicella Vaccination in Japan, South Korea, and EuropeThe Journal of Infectious Diseases, 2008
- Vaccination against Herpes Zoster and Postherpetic NeuralgiaThe Journal of Infectious Diseases, 2008
- Changing Varicella Epidemiology in Active Surveillance Sites—United States, 1995–2005The Journal of Infectious Diseases, 2008
- Varicella Vaccine Effectiveness in the US Vaccination Program: A ReviewThe Journal of Infectious Diseases, 2008
- A highly efficient protocol of generating and analyzing VZV ORF deletion mutants based on a newly developed luciferase VZV BAC systemJournal of Virological Methods, 2008